May 6, 2026 Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
May 6, 2026 Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation
